vs
Pacira BioSciences, Inc.（PCRX）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是Pacira BioSciences, Inc.的1.1倍（$200.5M vs $177.4M），ROGERS CORP净利率更高（2.2% vs 1.6%，领先0.6%），ROGERS CORP同比增速更快（5.2% vs 5.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -3.3%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
PCRX vs ROG — 直观对比
营收规模更大
ROG
是对方的1.1倍
$177.4M
营收增速更快
ROG
高出0.2%
5.0%
净利率更高
ROG
高出0.6%
1.6%
两年增速更快
PCRX
近两年复合增速
-3.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $200.5M |
| 净利润 | $2.9M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | 3.9% | — |
| 净利率 | 1.6% | 2.2% |
| 营收同比 | 5.0% | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $0.07 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXROG
| Q1 26 | $177.4M | $200.5M | ||
| Q4 25 | $196.9M | $201.5M | ||
| Q3 25 | $179.5M | $216.0M | ||
| Q2 25 | $181.1M | $202.8M | ||
| Q1 25 | $168.9M | $190.5M | ||
| Q4 24 | $187.3M | $192.2M | ||
| Q3 24 | $168.6M | $210.3M | ||
| Q2 24 | $178.0M | $214.2M |
净利润PCRXROG
| Q1 26 | $2.9M | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $5.4M | $8.6M | ||
| Q2 25 | $-4.8M | $-73.6M | ||
| Q1 25 | $4.8M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | $-143.5M | $10.7M | ||
| Q2 24 | $18.9M | $8.1M |
毛利率PCRXROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 79.5% | 31.5% | ||
| Q3 25 | 80.9% | 33.5% | ||
| Q2 25 | 77.4% | 31.6% | ||
| Q1 25 | 79.7% | 29.9% | ||
| Q4 24 | 78.7% | 32.1% | ||
| Q3 24 | 76.9% | 35.2% | ||
| Q2 24 | 75.1% | 34.1% |
营业利润率PCRXROG
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 3.5% | ||
| Q3 25 | 3.5% | 7.3% | ||
| Q2 25 | 4.7% | -33.3% | ||
| Q1 25 | 1.2% | -0.2% | ||
| Q4 24 | 13.2% | -6.6% | ||
| Q3 24 | -82.8% | 6.9% | ||
| Q2 24 | 15.9% | 5.3% |
净利率PCRXROG
| Q1 26 | 1.6% | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 3.0% | 4.0% | ||
| Q2 25 | -2.7% | -36.3% | ||
| Q1 25 | 2.8% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -85.1% | 5.1% | ||
| Q2 24 | 10.6% | 3.8% |
每股收益（稀释后）PCRXROG
| Q1 26 | $0.07 | $0.25 | ||
| Q4 25 | $0.05 | $0.20 | ||
| Q3 25 | $0.12 | $0.48 | ||
| Q2 25 | $-0.11 | $-4.00 | ||
| Q1 25 | $0.10 | $-0.08 | ||
| Q4 24 | $0.38 | $-0.04 | ||
| Q3 24 | $-3.11 | $0.58 | ||
| Q2 24 | $0.39 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $1.2B |
| 总资产 | $1.2B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXROG
| Q1 26 | $144.3M | $195.8M | ||
| Q4 25 | $238.4M | $197.0M | ||
| Q3 25 | $246.3M | $167.8M | ||
| Q2 25 | $445.9M | $157.2M | ||
| Q1 25 | $493.6M | $175.6M | ||
| Q4 24 | $484.6M | $159.8M | ||
| Q3 24 | $453.8M | $146.4M | ||
| Q2 24 | $404.2M | $119.9M |
总债务PCRXROG
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXROG
| Q1 26 | $653.9M | $1.2B | ||
| Q4 25 | $693.1M | $1.2B | ||
| Q3 25 | $727.2M | $1.2B | ||
| Q2 25 | $757.8M | $1.2B | ||
| Q1 25 | $798.5M | $1.3B | ||
| Q4 24 | $778.3M | $1.3B | ||
| Q3 24 | $749.6M | $1.3B | ||
| Q2 24 | $879.3M | $1.3B |
总资产PCRXROG
| Q1 26 | $1.2B | $1.4B | ||
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.6B | $1.5B |
负债/权益比PCRXROG
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流PCRXROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $43.7M | $46.9M | ||
| Q3 25 | $60.8M | $28.9M | ||
| Q2 25 | $12.0M | $13.7M | ||
| Q1 25 | $35.5M | $11.7M | ||
| Q4 24 | $33.1M | $33.7M | ||
| Q3 24 | $53.9M | $42.4M | ||
| Q2 24 | $53.2M | $22.9M |
自由现金流PCRXROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $43.5M | $42.2M | ||
| Q3 25 | $57.0M | $21.2M | ||
| Q2 25 | $9.3M | $5.6M | ||
| Q1 25 | $26.9M | $2.1M | ||
| Q4 24 | $31.0M | $18.3M | ||
| Q3 24 | $49.8M | $25.2M | ||
| Q2 24 | $51.6M | $8.8M |
自由现金流率PCRXROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 22.1% | 20.9% | ||
| Q3 25 | 31.7% | 9.8% | ||
| Q2 25 | 5.1% | 2.8% | ||
| Q1 25 | 15.9% | 1.1% | ||
| Q4 24 | 16.6% | 9.5% | ||
| Q3 24 | 29.6% | 12.0% | ||
| Q2 24 | 29.0% | 4.1% |
资本支出强度PCRXROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.1% | 2.3% | ||
| Q3 25 | 2.2% | 3.6% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 5.1% | 5.0% | ||
| Q4 24 | 1.1% | 8.0% | ||
| Q3 24 | 2.4% | 8.2% | ||
| Q2 24 | 0.9% | 6.6% |
现金转化率PCRXROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | 11.20× | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | 2.82× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
ROG
暂无分部数据
